Results 191 to 200 of about 187,458 (237)

Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. [PDF]

Cancer Immunol Immunother
Bopp AR, Lamenza FF, Upadhaya P, Ryan NM, Kazmierowicz N, Jordanides PP, Siddiqui A, Pracha SH, Roth P, Iwenofu OH, Oghumu S.   +10 more
europepmc   +1 more source

Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton's Tyrosine Kinase Inhibitor Acalabrutinib. [PDF]

Int J Mol Sci
Zhao Y, Chakraborty P, Tomassetti J, Subha T, Massé S, Thavendiranathan P, Billia F, Lai PFH, Abdel-Qadir H, Nanthakumar K.   +9 more
europepmc   +1 more source

Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors. [PDF]

JCI Insight
Schwarz E, Benner B, Wesolowski R, Quiroga D, Good L, Sun SH, Savardekar H, Li J, Jung KJ, Duggan MC, Lapurga G, Shaffer J, Scarberry L, Konda B, Verschraegen C, Kendra K, Shah M, Rupert R, Monk P, Shah HA, Noonan AM, Bixel K, Hays J, Wei L, Pan X, Behbehani G, Hu Y, Elemento O, Chung D, Xin G, Blaser BW, Carson WE.   +31 more
europepmc   +1 more source

Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024). [PDF]

Chin J Cancer Res
Song Z, Jiang D, Yu L, Chen Y, Zhou D, Li Y, Wu D, Zhang L, Miao L, Ma J, Zhu J, Jing H, Zhao R, Steering Committee OBOT, Evidence-Based Pharmacy Professional Committee Of Chinese Pharmaceutical Association Cpa TCPATESG, Chinese Pharmaceutical Association Cpa HPPCO, Chinese Pharmacological Society Cps DOTDMO, Clinical Oncology Csco ECOLOCSO, Chinese Society Of Clinical Oncology Csco ECOLO, China Anti-Cancer Association Caca SOICO, Chinese Medical Association Cma CSOHO, Cross-Straits Medicine Exchange Association Smea HPPCO.   +21 more
europepmc   +1 more source

E41K mutation activates Bruton's tyrosine kinase by stabilizing an inositol hexakisphosphate-dependent invisible dimer. [PDF]

J Biol Chem
Chowdhury S, Chakraborty MP, Roy S, Dey BP, Gangopadhyay K, Das R.   +5 more
europepmc   +1 more source

Bruton's tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax. [PDF]

Blood Cancer J
Coughlin CA, Chahar D, Lekakis M, Youssfi AA, Li L, Roberts E, Gallego NC, Volmar CH, Landgren O, Brothers S, Griswold AJ, Amador C, Bilbao D, Maura F, Schatz JH.   +14 more
europepmc   +1 more source

Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton's tyrosine kinase expression levels. [PDF]

Blood Cancer J
Kismali G, Manyam G, Jain N, Ivan C, Lamothe B, Ayres ML, Iles LR, Wierda WG, Gandhi V.   +8 more
europepmc   +1 more source